TFF Pharmaceuticals, Inc. (TFFP)
| Previous Close | 8.76 |
| Open | 8.78 |
| Bid | 8.01 x 1000 |
| Ask | 8.29 x 1000 |
| Day's Range | 8.19 - 9.00 |
| 52 Week Range | 8.07 - 21.14 |
| Volume | 154,224 |
| Avg. Volume | 201,635 |
| Market Cap | 210.27M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.04 |
| Earnings Date | Aug. 11, 2021 - Aug. 16, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.33 |
- GlobeNewswire
Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387
Data Shows AUG-3387 Neutralizes SARS-CoV-2 Delta Variant in Infective Assays Supports Earlier Data Showing AUG-3387 Binds Strongly to Delta Variant in Addition to Wild-Type Spike Protein and Other Variants of Concern Catalent Selected as Contract Drug Manufacturing Organization (CDMO) for AUG-3387 Scale-up Manufacturing for AUG-3387 Proceeding Rapidly; Early Batches Show Promising Results MENLO PARK, Calif. and AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) -- Augmenta Bioworks, a biotechnology c
- GlobeNewswire
TFF Pharmaceuticals to Participate in the BTIG Virtual Biotechnology Conference
AUSTIN, Texas, July 28, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that its President and CEO, Glenn Mattes, will be available for one-on-one meetings and will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:00pm EST. BTIG
- Zacks
TFF Pharmaceuticals (TFFP) Completes Enrollment in Phase I Study
TFF Pharmaceuticals (TFFP) completes enrollment in the phase I study on tacrolimus inhalation powder and announces positive preliminary data.
